Prospective Validation of MVP to Identify Areas for Prostate Cancer Biospy: Preliminary Results

  • ClinicalTrials.gov Identifier: NCT03585660

  • The purpose of the ongoing clinical trial is to test and validate MVP2for identificationof clinically significant tumor site for biopsy. 

  • 100 patients will be enrolled (34 patients enrolled so far)

  • Patients undergo a 12-core TRUS-guided sextant random biopsy.

  • Additional biopsy targets (UronavMR-US fusion biopsy)

    • Targets from expert radiologist's interpretation of clinicalmpMRI (PI-RADS ≥3)

    • Up to two additional biopsy targets per patient areselected by MVP Risk Map tool